Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
CalciMedica, Inc. reported three months ended June 30, 2023 results: net income $6.3 million, or $1.11 per share (basic and diluted), EPS $1.11 per share (basic and diluted).
- Period
- three months ended June 30, 2023
- Net income
- $6.3 million, or $1.11 per share (basic and diluted)
- EPS
- $1.11 per share (basic and diluted)
- Result
- reported results
Exact text from the filing
Net loss was $6.3 million, or $1.11 per share (basic and diluted), and $25.6 million, or $7.86 per share (basic and diluted), for the three and six months ended June 30, 2023, respectively.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CalciMedica, Inc. shareholders approved Election of Class III Directors at the 2023-08-09 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-08-09
Exact text from the filing
Proposal 1. Election of Class III Directors The Company’s stockholders elected the two persons listed below as Class III directors, each to serve a three-year term through the Company’s 2026 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CalciMedica, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-08-09 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-08-09
Exact text from the filing
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s principal independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov